

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

Using Topic Modeling via Non-negative Matrix Factorization to Identify Relationships between Genetic Variants and Disease Phenotypes: A Case Study of Lipoprotein(a) (*LPA*)

Juan Zhao¹, QiPing Feng², Patrick Wu¹, Jeremy L. Warner^{1,3}, Joshua C. Denny^{1,3}, Wei-Qi Wei^{1*}

¹Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA

²Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA

³Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

* Corresponding author

Email: wei-qi.wei@vanderbilt.edu

Department of Biomedical Informatics

2525 West End Ave., Suite 1500

Nashville, TN 37203

Tel: (615)343-1956

22 **Abstract**

23 Genome-wide and phenome-wide association studies are commonly used to identify
24 important relationships between genetic variants and phenotypes. Most of these studies have
25 treated diseases as independent variables and suffered from heavy multiple adjustment burdens
26 due to the large number of genetic variants and disease phenotypes. In this study, we propose
27 using topic modeling via non-negative matrix factorization (NMF) for identifying associations
28 between disease phenotypes and genetic variants. Topic modeling is an unsupervised machine
29 learning approach that can be used to learn the semantic patterns from electronic health record
30 data. We chose rs10455872 in *LPA* as the predictor since it has been shown to be associated with
31 increased risk of hyperlipidemia and cardiovascular diseases (CVD). Using data of 12,759
32 individuals from the biobank at Vanderbilt University Medical Center, we trained a topic model
33 using NMF from 1,853 distinct phecodes extracted from the cohort's electronic health records
34 and generated six topics. We quantified their associations with rs10455872 in *LPA*. Topics
35 indicating CVD had positive correlations with rs10455872 ($P < 0.001$), replicating a previous
36 finding. We also identified a negative correlation between *LPA* and a topic representing lung
37 cancer ($P < 0.001$). Our results demonstrate the applicability of topic modeling in exploring the
38 relationship between the genome and clinical diseases.

39

40 **Author summary**

41 Identifying the clinical associations of genetic variants remains crucial in understanding
42 how the human genome modulates disease risk. Traditional phenome-wide association studies
43 consider each disease phenotype as an independent variable, however, diseases often present as
44 complex clusters of comorbid conditions. In this study, we propose using topic modeling to
45 model electronic health record data as a mixture of topics (e.g., disease clusters or relevant
46 comorbidities) and testing associations between topics and genetic variants. Our results
47 demonstrated the feasibility of using topic modeling to replicate and discover novel associations
48 between the human genome and clinical diseases.

49

50

51

52 **Introduction**

53 Elucidating associations between genetic variants and human diseases creates new
54 avenues for disease prevention and enables more precise treatment of diseases [1,2]. During the
55 past two decades, genetic studies have uncovered thousands of genetic variants that influence
56 risk for disease phenotypes [3], e.g., the discovery of a variant in proprotein convertase
57 subtilisin/kexin type 9 (*PCSK9*[4]) associated with low plasma low-density lipoprotein, which
58 led to a new therapeutic drug class that was approved by the US Food and Drug Administration
59 in 2015. Many of these discoveries come from large-scale association analyses. The two most
60 notable approaches are genome-wide (GWAS) and phenome-wide association studies (PheWAS)
61 [2, 5]. For a given phenotype, GWAS scans hundreds of thousands to millions of single
62 nucleotide polymorphisms (SNPs) across the genome in a hypothesis-free approach. PheWAS,
63 on the contrary, analyzes thousands of disease phenotypes compared to a single SNP. In a
64 GWAS, the outcome variable is a disease phenotype and predictor variables are SNPs. While in
65 a PheWAS, the outcome variable is a SNP and predictor variables are disease phenotypes.

66 Association analyses test a large number of predictor variables at one time and assume
67 that each variable has an independent effect. However, diseases often occur together as a group
68 of comorbidities, e.g. hyperlipidemia (HLD) and cardiovascular diseases (CVDs). Conventional
69 association analyses may not capture the inter-connections among variables such as phenotypes
70 and thus may not be sensitive enough to identify important genotype-phenotype relationships.
71 Moreover, association analyses also face the challenge of scaling to an increasing number of
72 phenotypes. Previously, we have described a “networked PheWAS” approach which can address
73 interconnectivity but still requires a degree of supervised interpretation [6].

74 This study aimed to test the feasibility of topic modeling for identifying relationships
75 between genetic variants and disease phenotypes. Topic modeling is an unsupervised machine
76 learning method that was initially introduced as a text mining technique [7]. It has been
77 demonstrated to extract latent topics or themes from documents, aiding in the understanding of
78 large amounts of data [8]. Compared to traditional clustering approaches such as K-means
79 clustering that partitions a collection of documents into several disjoint clusters (i.e., topics)
80 based on a similarity measure, topic modeling assigns a document to multiple clusters with
81 different scores. Therefore, each document is characterized by one or more topics. In addition to
82 its wide adoption in the text mining field, topic modeling has achieved many successes in
83 computer vision and biomedical science. Recently, a few groups have used this approach to
84 analyze electronic health records (EHRs) [9,10] and genetic data to capture the characteristic of
85 data [11,12].

86 We hypothesized that topic modeling would be useful in replicating known findings and
87 uncovering previously unidentified relationships between genetic variants and disease
88 phenotypes. To test this hypothesis, we used topic modeling via non-negative matrix
89 factorization (NMF) [13,14] to identify latent topics (e.g. disease clusters or relevant
90 comorbidities) from EHR data. We then tested associations between the EHR-derived topics and
91 a *LPA* SNP (rs10455872). We chose the SNP because previous studies have shown that high-
92 levels of the *LPA* product (Lp(a)) is associated with increased risks of developing HLD and
93 CVD [15]. Specifically, rs10455872, as a single variant, explains 20-30% of the variation in
94 circulating Lp(a) levels, which makes it an ideal candidate for this study [16].

95 **Results**

96 We applied a topic modeling algorithm using NMF on the dataset of 12,759 individuals
97 and obtained six potentially meaningful topics from the EHRs (Fig 1). The learned topics (i.e.,
98 clusters of disease phenotypes) were consistent with the comorbidities associated with the
99 phenotypes most prevalent in the cohort. For example, topic #0 represented diseases of
100 respiratory failure, topic #2 defined diseases related to CVD (e.g., HLD, hypertension, and
101 chronic ischemic heart disease), topic #3 represented phenotypes relevant to lung cancer and its
102 treatment, topic #4 was related to diabetes and its comorbidities; and topic #5 was related to liver
103 disease and its sequelae.

104

105 **Fig 1. Word clouds for six topics.** The size of the words (phecode) in each cloud
106 indicate the weights of the phenotypes on the topic. Phenotypes with larger-sized words had
107 greater influence on the topic compared to phenotypes with smaller-sized words. For each word
108 cloud, we listed the top 60 words to provide a better visual presentation of what each topic
109 represents.

110 Fig 2 shows the distribution of the numbers of topics in the cohort. Topic #2 was the most
111 prevalent (33%) topic in the cohort. Topics #1 and #3 were the second and third most prevalent
112 topics in the cohort.

113

114 **Fig 2. Topic distribution in the cohort.** To visualize the prevalence of each topic in the
115 cohort, we assigned an individual to the topic with the maximum score.

116 We also used t-Distributed Stochastic Neighbor Embedding (t-SNE) [17] to transform the
117 individual-phenotypes matrix (W) into a 2-dimensional (2D) space to visualize the quality of

118 topic modeling (Fig 3). Each data point in the figure corresponds to one individual. We labeled
119 each individual with the assigned topic.

120

121 **Fig 3. t-SNE plot of visualizing the patient clusters in a projected 2D metric map.**

122 The perplexity was set to 30. We used PCA initialization as it is more globally stable. Each point
123 represents an individual. Topic #2 contains the most individuals in the cohort.

124 We then applied the Pearson correlation coefficient (PCC) to examine the association
125 between each topic and rs10455872. Statistical test results suggest that topic #2 and #3 were
126 significantly associated with rs10455872 (Table 1). Topic #2, a group of lipid and cardiovascular
127 diseases, had a positive correlation with rs10455872 ($r=0.072$, $p=5.8e-16$). We also found that
128 topic #3, a group of phenotypes relevant to lung cancer, had a negative correlation with
129 rs10455872 ($r=-0.039$, $p=8.5e-6$). Although the r coefficient is weaker than the topic#2, these
130 correlations are highly statistically significant.

131 **Table 1. Pearson correlation between LPA variant for each topic**

Topic	Top phenotypes in this topic	r	P value
#0	Respiratory failure, Pneumonia, Pleurisy, Pulmonary collapse; interstitial/compensatory emphysema, Hypotension NOS, Tachycardia NOS, Other dyspnea, Hypopotassemia, Sepsis, Septicemia	0.011	0.199
#1	Pain in joint, Other tests, Back pain, Pain in limb, Malaise and fatigue, Cough, Nonspecific chest pain, Essential hypertension, Osteoarthritis NOS, Abdominal pain	-0.008	0.358

#2	Coronary atherosclerosis, Essential hypertension, Hyperlipidemia, Congestive heart failure NOS, Nonspecific chest pain, Atrial fibrillation, Chronic ischemic heart disease, Shortness of breath, Nonrheumatic mitral valve disorders, Cardiomegaly	0.072	5.8e-16
#3	Chemotherapy, Tobacco use disorder, Lung cancer, Other diseases of lung, Malaise and fatigue, Secondary malignancy of lymph nodes, Secondary malignancy of lung, Nausea and vomiting, Nonspecific chest pain, Shortness of breath	-0.039	8.5e-6
#4	Type 2 diabetes, Hypertensive chronic kidney disease, Chronic renal failure, Insulin pump user, Type 2 diabetic neuropathy, Chronic Kidney Disease, Stage III, Type 2 diabetic nephropathy, Type 1 diabetes, Polyneuropathy in diabetes, Acute renal failure	0.002	0.783
#5	Ascites (nonmalignant), Abdominal pain, Cirrhosis of liver without mention of alcohol, Thrombocytopenia, Liver abscess and sequelae of chronic liver disease, Portal hypertension, Chronic nonalcoholic liver disease, Disorders of liver, Esophageal bleeding, Nausea and vomiting	-0.02	0.021

132

133 **Discussion**

134 Topic modeling has been widely used in the field of text mining. In this paper, we applied

135 this technique to explore associations between disease phenotypes and genetic variants. We

136 assumed that some disease phenotypes found simultaneously in a large EHR have correlated
137 semantic meanings and thus can be learned as topics. We examined the associations between a
138 *LPA* variant (rs10455872) and the six topics derived from EHRs. We observed the expected
139 association between rs10455872 and a topic representing CVD/HLD. We also found a novel
140 association, as of this writing [18], between the *LPA* variant and a lung cancer topic.

141 The *LPA* gene encodes lipoprotein (a), a major component of the Lp(a) particle.
142 Individuals with elevated Lp(a) levels are more likely to develop CVD compared to those with
143 normal or low Lp(a) level [16,19]. Approximately 70% of Lp(a) variation can be attributed to
144 variants at the *LPA* locus [20–22], and rs10455872 alone explains ~25% variation in circulating
145 Lp(a) levels [16]. Further, a previous genetic study suggested that *LPA* variants were strong
146 predictors for CVD risk [16]. In a more recent study of >10,000 patients taking statins, our group
147 found that rs10455872 predicted residual CVD risk while on lipid-lowering treatment [23]. This
148 study's finding of a significant association between rs10455872 and the CVD/HLD topic
149 demonstrates the feasibility of topic modeling as a critical tool for uncovering genotype-
150 phenotype relationships.

151 We also observed a negative correlation between the *LPA* variant and the cancer/lung
152 cancer topic, i.e., possessing this variant is protective. Previous epidemiological studies have
153 reported that individuals with low Lp(a) levels had increased risk of all-cause and cancer-related
154 mortality [24]. Mieno et al. found that hypolipoproteinemia(a) is a risk factor for cancer except
155 for lung cancer. Nevertheless, there are few reports on a relationship between cancer and *LPA*
156 polymorphism or expression levels. Our previous PheWAS analysis of a separate cohort
157 identified an association between rs10455872 and cancer diagnosis code with borderline
158 significance [23]. To further explore this association between rs10455872 and the cancer/lung

159 cancer topic, we queried gene2pheno (https://imlab.shinyapps.io/gene2pheno_ukb_neale/),
160 which is a publicly available database for testing associations between predicted gene expression
161 levels and phenotypes using data from the UK Biobank. Genetically predicted LPA expression
162 levels were associated with death from T cell lymphomas ($p=6.9 \times 10^{-5}$, Underlying (primary)
163 cause of death: ICD10: C84.5 Other and unspecified T-cell lymphomas). Given that lung cancer
164 is strongly mediated by environmental exposure and that tobacco use disorder was also part of
165 topic #4, it is possible that the SNP is a marker for propensity to smoking, e.g., similar to what
166 was shown for rs16969968 [25]. Further genetic and epidemiological studies are needed to
167 elucidate the relationship between Lp(a) levels and cancer incidence.

168 Topic modeling approaches require pre-specification of the number of topics. In this
169 study, we set $k=6$, because we aimed to capture the most prevalent diseases such as CVD and to
170 quantify the association. Increasing k allows the quantification of associations between genetic
171 variants and rare diseases but risks fracturing common phenotype clusters. It can be seen that
172 (Fig 3), except for topic #4 (diabetes), the learned topics formed distinct clusters, indicating a
173 good quality of topic modeling. Some of points in topic #4 (diabetes) were close with topic #2
174 (CVD), which was expected, because type II diabetes is an important risk factor that increases
175 the risk of developing CVD. Compared to the other topics, #1 (Pain), #2 (CVD), and #3 (Lung
176 Cancer) have more concentrated clusters.

177 For optimal selection of k , common approaches have used different values of k to look at
178 the error in optimization and selected the best value by having domain experts review the topics
179 to identify which set of topics are most meaningful, and have estimated k using singular value
180 decomposition (SVD) to look at the decay of singular values [26–28]. To provide evidence for

181 the stabilities of our results, we also set different numbers of topics $k=10, 20, 30$ (Supplementary
182 Table 1) and examined the PCC. Results were consistent with topics at $k=6$.

183 In summary, unlike traditional PheWAS that have treated each disease phenotype as a
184 distinct variable, topic modeling via NMF generates more abstract latent factors from disease
185 phenotypes and significantly reduces the number of multiple tests. Our results demonstrate the
186 power of topic modeling in the detection of comorbidities and previously unexplored genotype-
187 phenotype relationships among a large cohort.

188 **Limitations**

189 There are several limitations in this study. First, we tested only one genetic variant in one
190 gene. Rs10455872 explains approximate 25% change in circulating Lp(a) levels according to
191 previous studies; however, it would be interesting to generate a genetic risk score for Lp(a) levels
192 and test its association with disease phenotypes in the future. Second, we used a binary value to
193 indicate if an individual had a diagnosis code. A method accounting for disease severity (e.g.,
194 counts of diagnosis codes) could be used in future studies. Finally, the current study was limited
195 to using billing codes to phenotype individuals. We did not include other information, e.g.
196 laboratory test and medications, to assign more accurate phenotypes. This problem can be solved
197 in the future using more sophisticated “deep” phenotyping methods that include more features
198 from EHRs.

199

200 **Materials and methods**

201 **Study cohort**

202 We used data from BioVU, the de-identified DNA biobank at Vanderbilt University
203 Medical Center (VUMC), to conduct this study. BioVU contains DNA samples from >250,000
204 individuals that are linked with their de-identified EHRs, including diagnostic and procedure
205 codes, clinical notes, laboratory values and medications. We identified 12,759 adult individuals
206 of European ancestry (F/M: 6,018/6,741; age: 70.3±12.3) who had both EHRs and genotyped
207 data of rs10455872 available.

208 **rs10455872 Genotyping**

209 We extracted each individual's rs10455872 information from existing genotyped data.
210 All genotyping was previously conducted using commercially available genome-wide SNP
211 arrays with quality control criteria for variants followed by a standard imputation process using
212 1000 Genomes Project allele frequency estimates.

213 Among the cohort of 12,759 individuals, we observed 85.2% AA, 14.2% AG, 6.1% GG.
214 The minor allele frequency (MAF) of the rs10455872 G allele is 7.7% in our cohort, consistent
215 with the 7% MAF in the European population [29]. We used 0, 1, 2 to represent the number of
216 *LPA* rs10455872 G alleles that an individual carry.

217 **Disease Phenotypes**

218 Following established protocols used in past studies [30], we grouped each individual's
219 ICD-9-CM (International Classification of Disease, 9th edition) codes into disease phecodes.

220 There were 1853 phecodes present in the 12,759 individuals. For each phecode, we labeled
221 individuals without the phecode with a '0' and those with the phecode with a '1'.

222 We applied a topic modeling algorithm using NMF on the dataset of 12,759 individuals
223 to learn potentially meaningful topics from the EHRs. Then, we quantified the association
224 between each learned topic with rs10455872 using PCC. The workflow of this experiment is
225 demonstrated in Fig 4.

226

227 **Fig 4. Illustration of topic modeling on EHRs using NMF**

228 **Topic modeling via Non-negative Matrix Factorization (NMF)**

229 We used NMF as our topic modeling approach. NMF is a low-rank matrix approximation
230 algorithm that has been widely used for feature reduction for high-dimensional data. The
231 assumption is that given a large and sparse matrix X of size $n \times m$ representing a collection of n
232 high dimensional data points in R^m . X is low rank which means that most data points can be
233 approximately represented by a linear combination of a small set of k basis vectors $H \in R^{k \times n}$.
234 The linear combination is a coefficients matrix $W \in R^{n \times k}$ providing a lower-dimensional
235 encoding for X , which result in a feature reduction for a high-dimensional data. Since NMF
236 restricts the X non-negative and enforces the H and W to be also non-negative, NMF has good
237 interpretability and has been commonly used as a topic modeling approach in text mining.

238 We considered each individual's EHR as one document, and each document was
239 described by disease phenotypes represented by the phecodes (Fig 1). Since we had 12,759 (n)
240 individuals' EHRs and 1,853 (m) unique phecodes, we used matrix $X \in R^{n \times m}$ to represent the
241 input data, where each row of X represented an individual, and each column of X was a phecode.
242 The entry of the matrix $X_{ij} \in X$ was a binary value (0 or 1) indicating whether i th individual had

243 the j th phecode. This representation is similar with the bag-of-word model, where each document
244 is associated with a set of words, and word ordering in the documents does not matter.

245 Given that non-negative input matrix $X \in R^{n \times m}$, and an expected number of topics $k \leq m$,
246 NMF generates two matrices, $W \in R^{n \times k}$, and $H \in R^{k \times m}$. Both W and H are non-negative
247 entries, such that

$$248 \quad \min_{W \geq 0, H \geq 0} \|X - WH\|_F^2 + \lambda R(W, H) \quad (1)$$

249 $H(k, :)$ is a latent topic – phenotype matrix. Specifically, each row of H corresponds to a
250 disease topic, and each topic is represented by a set of relevant phenotypes that co-occurred in
251 several individuals' EHRs, with specific cores indicating their relevance to this topic. Through
252 $H(k, :)$, we extracted a semantic meaning of each topic, e.g. what kind of diseases or
253 comorbidities are represented by the topic.

254 $W(i, k)$ is an individual-topic matrix. Each row of W corresponds to an individual's score
255 on each topic that indicates the diseases and comorbidities carried by the individual. An
256 individual that has a large score for a disease topic indicates that there a higher probability for an
257 association between individual and the topic. $W(i, k)$ is then used for the association calculation
258 between the topics and rs10455872, which is described further below.

259 $R(W, H)$ is the regularization term that combines L1 and L2 norms, which is defined as:

$$260 \quad R(W, H) = \gamma(\|W\|_F + \|H\|_F) + \frac{1}{2}(1 - \gamma)(\|W\|_F^2 + \|H\|_F^2), \quad (3)$$

261 where γ is the ratio for L1 penalty. Adding the regularization term is necessary for
262 balancing the sparsity of the topics, meaning that an individual may have several topics at the
263 same time. Moreover, addition of the regularization term minimizes the effect of outliers on the
264 model.

265 **Statistical analysis**

266 We applied the PCC to quantify the association between each individuals' scores on
267 specific topic and each individual's rs10455872 status, for each learned topic. PCC measures the
268 strength of a linear association between two variables. PCC also can generate a correlation
269 coefficient denoted by $r \in [-1, 1]$, which shows the direction of the correlation.

270 We used the individual-topic matrix, $W \in R^{n \times k}$, generated by NMF to calculate the PCC
271 with the genetic variants. Each column vector of $W(:, j)$ of the matrix W represented a topic
272 vector with scores on all the individuals. We used each column vector as the predictor variable x
273 and the number of minor alleles (0, 1, or 2) at rs10455872 of each patient as variable y .

274 **References**

- 275 1. Denny JC, Van Driest SL, Wei W-Q, Roden DM. The Influence of Big (Clinical) Data and
276 Genomics on Precision Medicine and Drug Development. *Clinical Pharmacology &*
277 *Therapeutics*. 2018;103: 409–418. doi:10.1002/cpt.951
- 278 2. Manolio TA. Genomewide Association Studies and Assessment of the Risk of Disease. Feero
279 WG, Guttmacher AE, editors. *New England Journal of Medicine*. 2010;363: 166–176.
280 doi:10.1056/NEJMra0905980
- 281 3. Welter D, MacArthur J, Morales J, Burdett T, Hall P, Junkins H, et al. The NHGRI GWAS
282 Catalog, a curated resource of SNP-trait associations. *Nucleic Acids Res*. 2014;42: D1001-
283 1006. doi:10.1093/nar/gkt1229
- 284 4. Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in PCSK9, low LDL,
285 and protection against coronary heart disease. *N Engl J Med*. 2006;354: 1264–1272.
286 doi:10.1056/NEJMoa054013
- 287 5. Denny JC, Ritchie MD, Basford MA, Pulley JM, Bastarache L, Brown-Gentry K, et al.
288 PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene–disease
289 associations. *Bioinformatics*. 2010;26: 1205–1210. doi:10.1093/bioinformatics/btq126
- 290 6. Warner JL, Denny JC, Kreda DA, Alterovitz G. Seeing the forest through the trees:
291 uncovering phenomic complexity through interactive network visualization. *J Am Med*
292 *Inform Assoc*. 2015;22: 324–329. doi:10.1136/amiajnl-2014-002965

- 293 7. Arora S, Ge R, Moitra A. Learning Topic Models – Going Beyond SVD. Proceedings of the
294 2012 IEEE 53rd Annual Symposium on Foundations of Computer Science. Washington, DC,
295 USA: IEEE Computer Society; 2012. pp. 1–10. doi:10.1109/FOCS.2012.49
- 296 8. MacMillan K, Wilson JD. Topic supervised non-negative matrix factorization.
297 arXiv:170605084 [cs, stat]. 2017; Available: <http://arxiv.org/abs/1706.05084>
- 298 9. Pinoli P, Chicco D, Masseroli M. Enhanced probabilistic latent semantic analysis with
299 weighting schemes to predict genomic annotations. 13th IEEE International Conference on
300 BioInformatics and BioEngineering. 2013. pp. 1–4. doi:10.1109/BIBE.2013.6701702
- 301 10. Wahabzada M, Mahlein A-K, Bauckhage C, Steiner U, Oerke E-C, Kersting K. Plant
302 Phenotyping using Probabilistic Topic Models: Uncovering the Hyperspectral Language of
303 Plants. Scientific Reports. 2016;6: 22482. doi:10.1038/srep22482
- 304 11. McCoy TH, Castro VM, Snapper LA, Hart KL, Perlis RH. Efficient Genome-wide
305 Association in Biobanks Using Topic Modeling Identifies Multiple Novel Disease Loci. Mol
306 Med. 2017;23: 285–294. doi:10.2119/molmed.2017.00100
- 307 12. Backenroth D, He Z, Kiryluk K, Boeva V, Pethukova L, Khurana E, et al. FUN-LDA: A
308 Latent Dirichlet Allocation Model for Predicting Tissue-Specific Functional Effects of
309 Noncoding Variation: Methods and Applications. The American Journal of Human Genetics.
310 2018;102: 920–942. doi:10.1016/j.ajhg.2018.03.026
- 311 13. Sra S, Dhillon IS. Generalized Nonnegative Matrix Approximations with Bregman
312 Divergences. In: Weiss Y, Schölkopf B, Platt JC, editors. Advances in Neural Information
313 Processing Systems 18. MIT Press; 2006. pp. 283–290. Available:
314 [http://papers.nips.cc/paper/2757-generalized-nonnegative-matrix-approximations-with-](http://papers.nips.cc/paper/2757-generalized-nonnegative-matrix-approximations-with-bregman-divergences.pdf)
315 [bregman-divergences.pdf](http://papers.nips.cc/paper/2757-generalized-nonnegative-matrix-approximations-with-bregman-divergences.pdf)
- 316 14. Kim H, Park H. Sparse non-negative matrix factorizations via alternating non-negativity-
317 constrained least squares for microarray data analysis. Bioinformatics. 2007;23: 1495–1502.
318 doi:10.1093/bioinformatics/btm134
- 319 15. Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, et al. Lipoprotein(a)
320 as a cardiovascular risk factor: current status. Eur Heart J. 2010;31: 2844–2853.
321 doi:10.1093/eurheartj/ehq386
- 322 16. Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, et al. Genetic Variants
323 Associated with Lp(a) Lipoprotein Level and Coronary Disease. New England Journal of
324 Medicine. 2009;361: 2518–2528. doi:10.1056/NEJMoa0902604
- 325 17. Maaten L van der, Hinton G. Visualizing Data using t-SNE. Journal of Machine Learning
326 Research. 2008;9: 2579–2605.
- 327 18. rs10455872 - SNPedia [Internet]. [cited 23 May 2018]. Available:
328 <https://www.snpedia.com/index.php/Rs10455872>

- 329 19. Khera AV, Emdin CA, Drake I, Natarajan P, Bick AG, Cook NR, et al. Genetic Risk,
330 Adherence to a Healthy Lifestyle, and Coronary Disease. *New England Journal of Medicine*.
331 2016;375: 2349–2358. doi:10.1056/NEJMoa1605086
- 332 20. Barlera S, Specchia C, Farrall M, Chiodini BD, Franzosi MG, Rust S, et al. Multiple QTL
333 influence the serum Lp(a) concentration: a genome-wide linkage screen in the PROCARDIS
334 study. *Eur J Hum Genet*. 2007;15: 221–227. doi:10.1038/sj.ejhg.5201732
- 335 21. Berglund L, Ramakrishnan R. Lipoprotein(a): an elusive cardiovascular risk factor.
336 *Arterioscler Thromb Vasc Biol*. 2004;24: 2219–2226.
337 doi:10.1161/01.ATV.0000144010.55563.63
- 338 22. Sandholzer C, Hallman DM, Saha N, Sigurdsson G, Lackner C, Császár A, et al. Effects of
339 the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic
340 groups. *Hum Genet*. 1991;86: 607–614.
- 341 23. Wei W-Q, Li X, Feng Q, Kubo M, Kullo IJ, Peissig PL, et al. LPA Variants are Associated
342 with Residual Cardiovascular Risk in Patients Receiving Statins. *Circulation*. 2018;
343 CIRCULATIONAHA.117.031356. doi:10.1161/CIRCULATIONAHA.117.031356
- 344 24. Low Lipoprotein(a) Concentration Is Associated with Cancer and All-Cause Deaths: A
345 Population-Based Cohort Study (The JMS Cohort Study) [Internet]. [cited 14 May 2018].
346 Available: <http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0031954>
- 347 25. Lips EH, Gaborieau V, McKay JD, Chabrier A, Hung RJ, Boffetta P, et al. Association
348 between a 15q25 gene variant, smoking quantity and tobacco-related cancers among 17 000
349 individuals. *Int J Epidemiol*. 2010;39: 563–577. doi:10.1093/ije/dyp288
- 350 26. Bioucas-Dias JM, Nascimento JMP. Estimation of signal subspace on hyperspectral data.
351 *Image and Signal Processing for Remote Sensing XI*. International Society for Optics and
352 Photonics; 2005. p. 59820L. doi:10.1117/12.620061
- 353 27. Tan VYF, Févotte C. Automatic Relevance Determination in Nonnegative Matrix
354 Factorization with the /spl beta/-Divergence. *IEEE Transactions on Pattern Analysis and
355 Machine Intelligence*. 2013;35: 1592–1605. doi:10.1109/TPAMI.2012.240
- 356 28. Kanagal B, Sindhvani V. Rank Selection in Low-rank Matrix Approximations: A Study of
357 Cross-Validation for NMFs. : 5.
- 358 29. 1000 Genomes Project Consortium, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang
359 HM, et al. A global reference for human genetic variation. *Nature*. 2015;526: 68–74.
360 doi:10.1038/nature15393
- 361 30. Martin PA, Thorburn MJ, Smith-Read EH. Chromosomal rearrangements in three
362 generations of a Jamaican family. A possible further example of recombinational imbalance.
363 *Cytogenetics*. 1970;9: 360–368.

365 **Supporting Information**

366 **S1 Table. Results with *topic k=10, 20,30***

367

368

369





